Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.40 |
| ▸ | IL1B | P01584 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813360 | 0.86 | CNR2 (0.42) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL2810161 | 0.83 | REN (0.35) | RENKCNH2CNR2CNR1 | |
| SCHEMBL13131417 | 0.81 | REN (0.45) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL2805458 | 0.80 | HTR4 (0.37) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL2812256 | 0.77 | REN (0.63) | RENKCNH2 | |
| SCHEMBL1070942 | 0.73 | REN (0.44) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL13131362 | 0.70 | REN (0.51) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL2805278 | 0.70 | CDC25A (0.45) | CNR2CNR1 | |
| SCHEMBL3566159 | 0.69 | CNR2 (0.40) | RENKCNH2CNR2CNR1P2RX7 | |
| SCHEMBL2035744 | 0.68 | CNR1 (0.49) | CNR2CNR1P2RX7IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885KCNH2 39/4885CNR2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.